STXSHealthcare · Medical Instruments & SuppliesThe 4 Wall Street analysts covering Stereotaxis, Inc. hold a median 12-month price target of $4 — +187.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 30 of 100 as at 17 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Stereotaxis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (82): Sales and profits are climbing, and climbing faster than before.
Momentum (15): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on STXS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +187.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Aug 2026 | TD Cowen | Maintains | Buy | — |
| 13 May 2026 | Piper Sandler | Reiterates | Overweight | — |
| 16 Dec 2025 | Citizens | Initiates | Market Outperform | — |
| 12 Nov 2025 | Roth Capital | Reiterates | Buy | — |
| 5 Nov 2025 | Roth Capital | Reinstates | Buy | $4.00 |
| 5 Mar 2024 | Lake Street | Maintains | Buy | — |
| 5 Mar 2024 | Roth MKM | Reiterates | Buy | — |
| 10 Jan 2024 | Roth MKM | Initiates | Buy | — |
| 6 Mar 2023 | B. Riley Securities | Maintains | Buy | — |
| 6 Mar 2023 | Lake Street | Maintains | Buy | — |
| 6 Mar 2023 | Piper Sandler | Maintains | Overweight | — |
| 11 Nov 2022 | Cowen & Co. | Maintains | Outperform | — |
| 2 Sept 2022 | B. Riley Securities | Initiates | Buy | — |
| 12 July 2022 | Aegis Capital | Initiates | Buy | — |
| 23 June 2022 | B. Riley Securities | Initiates | Buy | — |
| 5 Jan 2022 | Craig-Hallum | Initiates | Buy | — |
| 5 Jan 2022 | Loop Capital | Initiates | Buy | — |
| 26 May 2021 | Piper Sandler | Initiates | Overweight | — |
| 8 Sept 2020 | Northland Capital Markets | Initiates | Outperform | — |
| 9 Apr 2020 | Cowen & Co. | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. STXS appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 90% of US stocks
Cheaper than 28% of US stocks
Cheaper than 11% of US stocks
Cheaper than 82% of US stocks
Higher than 14% of US stocks
Higher than 22% of US stocks
Higher than 74% of US stocks
Higher than 16% of US stocks
Higher than 8% of US stocks
Higher than 7% of US stocks
Higher than 16% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Stereotaxis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Stereotaxis, Inc. published the transcript of its Q2 2026 earnings call, as covered by Seeking Alpha. The item is a record of the company's quarterly earnings call discussion.
Why it matters — STXS watchers would care because the transcript provides direct insight into management's commentary on the company's quarterly financial results and operations.
Stereotaxis reported second-quarter 2026 revenue of $7.7 million. Growth in sales of its robotic catheter portfolio helped lift recurring revenue to a multiyear high, despite lower system revenue and continued supply constraints.
Why it matters — STXS watchers would care because the earnings report shows rising recurring revenue from the robotics portfolio despite ongoing system-revenue declines and supply constraints.
Stereotaxis reported a second-quarter loss of $0.05 per share, wider than the Zacks Consensus Estimate loss of $0.03 and matching the year-ago loss, while also lagging revenue estimates.
Why it matters — The results missed analyst expectations on both earnings and revenue, which matters for investors monitoring Stereotaxis's quarterly financial performance.
Stereotaxis reported its second quarter 2026 financial results and business updates for the period ended June 30, 2026, via a news release dated August 11, 2026. The company is described as a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention.
Why it matters — STXS watchers rely on quarterly results and business updates as the primary indicator of the company's operational performance and strategic progress.
The 4 Wall Street analysts covering Stereotaxis, Inc. have a median 12-month price target of $4, with estimates ranging from $3.5 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Stereotaxis, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Stereotaxis, Inc. 30 out of 100 across roughly 4,600 US stocks as at 17 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 17 Aug 2026, Stereotaxis, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (82 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +187.8% from the last close, and Ticker Nerd's factor model ranks Stereotaxis, Inc. 30 out of 100 as at 17 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Stereotaxis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for STXS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3.5 to $5 over the next 12 months.
Stereotaxis, Inc. returned -49.1% over the 12 months to 17 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Stereotaxis Inc. is a cutting-edge medical technology company that specializes in robotic systems for minimally invasive surgery.
The most recent item we track (Seeking Alpha, 12 Aug 2026): "Stereotaxis, Inc. (STXS) Q2 2026 Earnings Call Transcript". Stereotaxis, Inc. published the transcript of its Q2 2026 earnings call, as covered by Seeking Alpha. The item is a record of the company's quarterly earnings call discussion.
Stereotaxis Inc. is a cutting-edge medical technology company that specializes in robotic systems for minimally invasive surgery. The company's primary focus is on the development and commercialization of robotic navigation technologies designed to enhance the precision, safety, and efficiency of procedures within the cardiac arrhythmia treatment sector. Stereotaxis' flagship product, the Niobe Magnetic Navigation System, enables physicians to maneuver catheters with a high degree of accuracy, using magnetic fields to decrease potential complications associated with traditional manual techniques. This technology significantly impacts the healthcare sector, particularly hospitals and medical centers specializing in interventional cardiology, by improving patient outcomes and operational workflows. Based in St. Louis, Missouri, Stereotaxis plays a significant role in advancing the field of robotic surgery, contributing to the broader medical device market's growth and innovation.
CEO Dr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A. · 131 employees · United States · https://www.stereotaxis.com